Study of BMS-663513 in Patients With Advanced Cancer
This is a Phase I/II, ascending, multi-dose study of BMS-663513, an agonistic anti-CD137 monoclonal antibody, administered every three weeks to patients with metastatic or locally advanced solid tumors.
Tumors
DRUG: BMS-663513
Assess Safety (Number and distribution and severity adverse events) of subjects, Active treatment of a minimum of 3 months up until disease progression or toxicity; and long-term follow-up to assess time to progression or death will conclude 2 years after the last treatment with BMS-663513.
Efficacy by evaluation of tumor response, At week 12 and every 6 weeks thereafter. Follow-up up to 2 years after last dose of study drug|Assess pharmacokinetic parameters deriving from serum concentration versus time data, Cycle 1 Day 1, Cycle 2 Day 1 and 28, Cycle 3 Day 1 and 8, and Day 1 of every cycle the subject is on study from Cycle 4 and greater; and at study discharge.|Assess pharmacodynamic and immune response analysis, up to 60 days after last dose of study drug
This is a Phase I/II, ascending, multi-dose study of BMS-663513, an agonistic anti-CD137 monoclonal antibody, administered every three weeks to patients with metastatic or locally advanced solid tumors.